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ABSTRACT
Background. Growing epidemiological evidence demon-
strates increased zoster risks in people with chronic kidney
disease (CKD). Study objectives were to determine zoster
vaccine effectiveness in individuals with CKD in pragmatic
use.
Methods. A population-based cohort study was undertaken in
a 5% random sample of USMedicare from 2007 to 2009 involv-
ing 766 330 eligible individuals aged ≥65 years who were
(29 785) and were not (736 545) exposed to the zoster vaccine.
Incidence rates for zoster in vaccinated and unvaccinated indi-
viduals and hazard ratios for zoster comparing vaccinated
with unvaccinated were determined for individuals with
CKD. Time-updated Cox proportional hazards models were
used, adjusting for relevant confounders.
Results.CKDwas present in 183 762 (24%) of individuals (15%
of vaccinees). Adjusted vaccine effectiveness [95% conﬁdence
intervals (CIs)] in individuals with CKD was 0.49 (0.36–
0.65). The adjusted vaccine effectiveness in participants with
both CKD and diabetes mellitus was 0.46 (95% CI 0.09–0.68).
Vaccine effectiveness estimates were similar to those previously
reported for the general population [vaccine effectiveness 0.48
(95% CI 0.39–0.56)].
Conclusions. Zoster vaccine is effective against incident
zoster in older individuals with CKD. Extra efforts are war-
ranted to increase vaccine uptake in individuals with CKD
given the known low uptake in these higher risk individuals.
Keywords: chronic kidney disease, herpes zoster vaccine,
vaccine effectiveness
INTRODUCTION
Zoster is a major public health problem associated with signiﬁ-
cant morbidity, including prolonged, severe pain, namely post-
herpetic neuralgia (PHN). PHN is usually deﬁned as pain that
persists for 3 months or greater following incident zoster [1].
The effective live zoster vaccine was introduced in the USA for
immunocompetent individuals aged ≥60 years [2].
Increasing epidemiological evidence supports an increased risk
of zoster in individuals with chronic kidney disease (CKD) [3, 4].
For example, we reported that older beneﬁciarieswithCKDwere at
increased risk of zoster, adjusted hazard ratio 1.16 [95% conﬁdence
interval (CI) 1.11–1.21] [5]. There is also evidence to suggest that
developing zostermay be detrimental to individuals with CKD [6].
We also showed that older individuals in US Medicare with
CKD were less likely to receive the zoster vaccine compared
with people without CKD [5]. If the vaccine is similarly effective
in peoplewithCKD, the absolute beneﬁts of zoster vaccinationwill
be higher among peoplewithCKDgiven their higher baseline risk.
Therefore, we assessed zoster vaccine effectiveness among people
with CKD. Diabetes is the leading cause of end-stage renal disease
internationally, and pre-dialysis CKD frequently co-exists with
diabetes mellitus; [7, 8] diabetes has also been proposed as a pos-
sible risk factor for zoster [9]. Therefore, we additionally assessed
vaccine effectiveness in people with CKD and diabetes mellitus.
MATERIALS AND METHODS
The methods for this study have been described in detail previ-
ously [5]; a brief summary is given below.
This study used the 5% randomMedicare Standard Analytic
Files including Denominator, Inpatient hospital discharge re-
cords (MedPAR), Physician/Supplier (Carrier) and Outpatient
ﬁles from January 2007 to December 2009. The study popula-
tion were identiﬁed as previously described and comprised eli-
gible individuals aged≥65 years [5]. Individuals start of follow-
up was the ﬁrst date they fulﬁlled study eligibility criteria (at
least 12-months continuous enrolment with eligibility for
treatment under Medicare parts A, B and D) with an addition-
al 12 month baseline pre-study observation period added to
ensure observation of incident rather than prevalent zoster.
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The end of follow-up was deﬁned as the earliest of end of
eligibility, date of death, development of herpes zoster or the
end of the study period. Individuals enrolled in health main-
tenance organizations were excluded from the study as infor-
mation on clinical events is not available. Individuals with
episodes of herpes zoster in the ﬁrst year pre-study observa-
tion period or those who received the herpes zoster vaccine
during the baseline pre-study observation period were ex-
cluded from analysis. Exposure to the herpes zoster vaccine
was identiﬁed based on Current Procedural Terminology
(CPT) code 90736 or the National Drug Codes (NDC) for
the herpes zoster vaccine. If CPT code 90741 or Healthcare
Common Procedural Coding System (HCPCS) code G0377
was present within 7 days of vaccine purchase, that would be
considered the date of vaccination, otherwise the date of re-
cording of the NDC code for herpes zoster vaccine was consid-
ered to be the administration date. Incident herpes zoster was
identiﬁed by the presence of a speciﬁc International Classiﬁ-
cation of Diseases, Ninth Revision, Clinical Modiﬁcation
(ICD-9-CM) diagnostic code for herpes zoster, and the use
of systemic antiviral therapy, within 7 days either before or
after the diagnostic code for herpes zoster [10]. Cases were
identiﬁed from outpatient, inpatient or healthcare provider
(Carrier) ﬁles.
CKD, diabetes mellitus and kidney transplants were identi-
ﬁed from records by the presence of two or more ICD-9-CM
codes for each exposure on different days in the outpatient or
carrier ﬁles or one or more codes from inpatient records.
Chronic dialysis was deﬁned as the presence of at least two dia-
lysis codes separated by 30 days and within 365 days. Covariates
were identiﬁed as previously described [5].
Incidence rates for zoster by population characteristics
were determined by dividing events by person-years of follow-
up. Cox regression was used to derive hazard ratios for zoster
in vaccinees compared with the unvaccinated, adjusting for
age, gender, race, low income, immunosuppression (including
immunosuppression related to biologic therapies) and other
comorbidities including immune-mediated disorders (sys-
temic lupus erythematosus, inﬂammatory bowel disease and
rheumatoid arthritis) and disorders such as chronic obstruct-
ive pulmonary disease, previously reported to increase zoster
risk, Age and immunosuppression were included as time-
varying covariates. Hazard ratios for zoster in vaccinees com-
pared with the unvaccinated were determined for individuals
with CKD, diabetes mellitus and both disorders. To ensure
that the ﬁndings applied to pre-dialysis CKD, a sensitivity
analysis was undertaken excluding individuals with evidence
of dialysis or a renal transplant. Vaccine effectiveness (VE)
was calculated as VE = 1-hazard ratio of zoster in those vacci-
nated compared with individuals who did not receive the
vaccine.
RESULTS
The study population comprised 766 330 individuals, of whom
29 785 individuals were vaccinated. CKD was present in
183 762 (24%) of individuals (15% of vaccinees), 300 015
(39.2%) had diabetes mellitus (29% of vaccinees) and 106 026
(14%) had both diseases (7% of vaccinees) (Table 1). Kidney
disease stagewas available for 42% of the study cohort (Table 1),
with the majority of those with identiﬁable disease stage having
stage 3 CKD. A small minority of the population were on renal
replacement therapy, with 11 742 individuals on dialysis, of
whom 97 (0.3%) were vaccinated and 733 individuals with evi-
dence of a renal transplant, of whom 15 were vaccinated (0.1%).
Zoster incidence rates were higher in unvaccinated individuals
with CKD (11.4 per 1000 person-years, 95% CI 11.0–11.8) com-
pared with the unvaccinated population overall (10.0 per 1000
person years, 95% CI 9.8–10.2). Zoster incidence was increased
to a similar extent in those unvaccinated individuals with both
CKD and diabetes mellitus (11.0 per 1000 person years, 95% CI
10.5–11.5; Table 2), compared with the unvaccinated population.
Amongst thosewithCKD, the zoster incidence rate in those not
vaccinated was nearly double that in vaccinees (11.4 per 1000
person-years, 95%CI 11.0–11.8 in vaccinees with CKD, compared
with 6.4 per 1000 person years, 95% CI 4.4–9.2 in thosewith CKD
whowere not vaccinated; Table 2). AdjustedVE in individualswith
CKD was 0.49 (95% CI 0.36–0.65). Among individuals with both
CKD and diabetesmellitus, incidence rates in those not vaccinated
were 11.0 (95% CI 10.5–11.5) and 6.5 per 1000 person-years (95%
CI 3.8–10.9) in vaccinees, giving an adjusted VE of 0.46 (95% CI
0.09–0.68) (Table 2). A sensitivity analysis excluding beneﬁciaries
with evidence of either renal transplants or dialysis did not alter
study ﬁndings (data not shown).
DISCUSSION
Zoster incidence rate was higher in those with CKD and in
those with CKD and diabetes mellitus compared with indivi-
duals without these conditions. Zoster VE in beneﬁciaries
with CKD and with both CKD and diabetes mellitus was simi-
lar to VE in the overall study population [vaccine effectiveness
0.48 (95% CI 0.39–0.56)] [5].
Medicare beneﬁciaries are reasonably representative of the
older US population; 98% of Americans aged ≥65 years were
enrolled in Medicare in 2009 [11]. Our study is large, giving
power to assess VE in individuals with CKD. Despite having
adequate power to determine VE in the CKD cohort, our
study size was insufﬁcient to enable study of VE against PHN.
Additionally, there were too few events amongst individuals on
dialysis or with transplants to enable study of VE in these sub-
groups. VE was determined after adjusting for a wide range of
confounders. Medicare is an administrative data source, hence
there could be misclassiﬁcation of exposures and outcomes
which may have led to a bias towards the null.
Information on CKD stage was only available for 42% of indi-
viduals with CKD, hence it is not possible to comment on the VE
of the zoster vaccine by CKD stage. Additionally, the study period
was relatively short (maximum 2 years), due to data costs and
availability issues, hence we could not determine long-term vac-
cine effectiveness. Although the vaccine was licensed in 2006 and
recommended by the Advisory Committee on Immunization
Practices later that year, publication of the recommendation to
vaccinate was delayed, which may have contributed to the low
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uptake of this vaccine. Uptake of the zoster vaccine remains low,
but has gradually increased over time [12].
We have previously found that individuals with CKD were
less likely to have received the zoster vaccine than people without
CKD [5]. Previous studies have also reported increased incidence
of zoster in adults with CKD and in those being treated with
dialysis compared with those without CKD [3, 4, 13]. A recent
retrospective cohort study fromTaiwan reported a 27% increased
zoster incidence in those with CKD compared with those with-
out CKD and higher risks in those receiving renal replacement
therapy [4]. To our knowledge, no previous study has assessed
the VE of zoster vaccine in individuals with CKD. Good clinical
and serological responses have been reported for the varicella
vaccine in CKD in paediatric populations; however, the dose of
the latter vaccine is 14 times lower than the zoster vaccine with
distinct recommendations for use [2, 14, 15].
Table 2. Vaccine effectiveness in people with chronic kidney disease and diabetes mellitus
Vaccination status Events Person-years
(py) (1000)
Incidence rate per
1000 py (95% CI)
Crude hazard ratio
(95% CI)
Adj. hazard ratioa
(95% CI)
Unvaccinated overall 12 958 1291.8 10.0 (9.8–10.2) 1.0 1.0
Vaccinated overall 154 28.3 5.4 (4.6–6.4) 0.55 (0.47–0.64) 0.52 (0.44–0.61)
Unvaccinated CKD 3438 302.0 11.4 (11.0–11.8) 1.0 1.0
Vaccinated CKD 28 4.4 6.4 (4.4–9.2) 0.56 (0.39–0.81) 0.51 (0.35–0.74)
Unvaccinated diabetes mellitus 5181 509.2 10.2 (9.9–10.4) 1.0 1.0
Vaccinated diabetes mellitus 46 8.4 5.4 (4.1–7.3) 0.54 (0.40–0.72) 0.50 (0.38–0.67)
Unvaccinated CKD and diabetes mellitus 1926 174.9 11.0 (10.5–11.5) 1.0 1.0
Vaccinated CKD and diabetes mellitus 14 2.2 6.5 (3.8–10.9) 0.59 (0.35–1.00) 0.54 (0.32–0.91)
aAdjusted for age, gender, race, low income, immunosuppression, other comorbidities including immune-mediated disorders (systemic lupus erythematosus, inﬂammatory bowel disease
and rheumatoid arthritis) and chronic obstructive pulmonary disease, with age and immunosuppression as time-varying covariates.
Table 1. Demographics of the study population
Characteristic Population overall
n (%)
Individuals vaccinated
n (%)
n = 29 785
Individuals not vaccinated
n (%)
n = 736 545
Age (years)a
65–69 209 992 (27.4) 8805 (29.6) 201 187 (27.3)
70–74 160 022 (20.9) 7994 (26.8) 152 028 (20.6)
75–79 141 884 (18.5) 6127 (20.6) 135 757 (18.4)
≥80 254 432 (33.2) 6859 (23.0) 247 573 (33.6)
Gender
Male 247 940 (32.4) 9111 (30.6) 238 829 (32.4)
Female 518 390 (67.7) 20 674 (69.4) 497 716 (67.6)
Raceb
White 646 803 (84.4) 27 889 (93.6) 618 914 (84.0)
Black 66 506 (8.7) 387 (1.3) 66 119 (9.0)
Other 52 046 (6.8) 1509 (5.1) 51 512 (7.0)
Low income
No 570 182 (74.4) 27 405 (92.0) 542 777 (73.7)
Yes 196 148 (25.6) 2380 (8.0) 193 768 (26.3)
CKD
No 582 568 (76.0) 25 261 (84.8) 557 307 (75.7)
Yes 183 762 (24.0) 4524 (15.2) 179 238 (24.3)
Stage unavailable 107 101 (58.3) 2661 (8.9) 104 440 (14.2)
CKD Stage 1 4702 (0.6) 136 (0.5) 4566 (0.6)
CKD Stage 2 8348 (1.1) 274 (0.9) 8704 (1.1)
CKD Stage 3 37 142 (4.9) 1123 (3.8) 36 019 (4.9)
CKD Stage 4 10 039 (1.3) 166 (0.6) 9.873 (1.3)
CKD Stage 5 16 430 (2.1) 164 (0.1) 16 266 (2.2)
CKD Stage 5—on renal replacement therapy
On dialysis 11 742 (1.5) 97 (0.3) 11 645 (1.6)
Renal transplantation 773 (0.1) 15 (0.1) 758 (0.1)
Diabetes mellitus
No 466 315 (60.9) 21 029 (70.6) 445 286 (60.5)
Yes 300 015 (39.2) 8756 (29.4) 291 259 (39.5)
CKD and diabetes mellitus
No 660 304 (86.2) 27 569 (92.6) 632 735 (85.9)
Yes 106 026 (13.8) 2216 (7.4) 103 810 (14.1)
aFor determination of numbers, age at vaccination used if vaccinated; otherwise baseline age.
bMissing race information for 975 people (0.1%).
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CKD is associated with immunosuppression with increasing
immune defects, including reduced naïve and memory T cells
in association with declining renal function. In those with
end-stage renal disease, infection is a cause of signiﬁcant mor-
bidity and mortality, and is second only to cardiovascular
disease as a cause of death [16]. Defective cellular and humoral
immunity in CKD and end-stage renal disease are not only
contributing factors to the predisposition to develop infections,
but may also lead to reduced VE [17]. Previous studies have
reported reduced seroconversion rates and lower and more
quickly declining antibody titres in patients with CKD, leading
to the requirement to use booster doses and suboptimal vaccine
responses; booster doses are not recommended for the zoster
vaccine [17].
We have shown that, despite reduced vaccine uptake in peo-
ple with CKD and in those with CKD coexisting with diabetes
mellitus, and despite concerns about reduced effectiveness in
CKD, the zoster vaccine is effective in these beneﬁciaries with
similar levels of effectiveness to the general older US popula-
tion. Extra efforts are warranted to increase vaccine uptake in
people with CKD in the USA and in the UK according to guide-
lines. The greater absolute beneﬁts from vaccinating people
with CKD should inform cost-effectiveness analyses and inﬂu-
ence vaccination policies. This novel timely study is of particu-
lar relevance in the early stages of introducing a large scale
vaccination programme.
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